Comprehensive Stock Comparison
Compare Inhibrx Biosciences, Inc. (INBX) vs Revolution Medicines, Inc. (RVMD) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety | INBX | Beta 0.74 vs RVMD's 0.99, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | INBX | +459.5% vs RVMD's +150.4% |
| Efficiency (ROA) | RVMD | -48.0% ROA vs INBX's -87.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapeutics for life-threatening conditions like cancer. It generates no revenue currently — funding operations through equity offerings and partnerships while advancing multiple candidates through clinical trials. Its competitive advantage lies in proprietary single-domain antibody (sdAb) technology platforms that enable creation of multi-specific biologics with potentially superior therapeutic profiles.
Revolution Medicines is a clinical-stage biotechnology company developing precision oncology therapies targeting RAS-addicted cancers. It generates revenue primarily through research collaborations and milestone payments — notably from its partnership with Sanofi on SHP2 inhibitors — while advancing its pipeline toward potential future drug sales. The company's competitive advantage lies in its deep expertise in RAS biology and its portfolio of novel inhibitors targeting multiple RAS pathway vulnerabilities that have historically been difficult to drug.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
INBX leads in 1 of 6 categories — strongest in Financial Metrics. 4 categories are tied.
Financial Metrics (TTM)
INBX and RVMD operate at a comparable scale, with $1M and $0 in trailing revenue.
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| RevenueTrailing 12 months | $1M | $0 |
| EBITDAEarnings before interest/tax | -$151M | -$1.2B |
| Net IncomeAfter-tax profit | -$155M | -$1.1B |
| Free Cash FlowCash after capex | -$143M | -$914M |
| Gross MarginGross profit ÷ Revenue | -86.3% | — |
| Operating MarginEBIT ÷ Revenue | -110.0% | — |
| Net MarginNet income ÷ Revenue | -110.8% | — |
| FCF MarginFCF ÷ Revenue | -102.5% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +19.7% | -68.1% |
Valuation Metrics
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| Market CapShares × price | $1.1B | $20.1B |
| Enterprise ValueMkt cap + debt − cash | $930M | $19.9B |
| Trailing P/EPrice ÷ TTM EPS | 0.64x | -17.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5373.68x | — |
| Price / BookPrice ÷ Book value/share | 8.03x | 11.89x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
RVMD delivers a -69.3% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-4 for INBX. INBX carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to RVMD's 0.10x. On the Piotroski fundamental quality scale (0–9), INBX scores 4/9 vs RVMD's 1/9, reflecting mixed financial health.
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| ROE (TTM)Return on equity | -4.2% | -69.3% |
| ROA (TTM)Return on assets | -87.4% | -48.0% |
| ROICReturn on invested capital | — | -54.3% |
| ROCEReturn on capital employed | -169.3% | -53.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 1 |
| Debt / EquityFinancial leverage | 0.06x | 0.10x |
| Net DebtTotal debt minus cash | -$145M | -$225M |
| Cash & Equiv.Liquid assets | $153M | $384M |
| Total DebtShort + long-term debt | $8M | $159M |
| Interest CoverageEBIT ÷ Interest expense | -16.21x | -49.69x |
Total Returns (with DRIP)
A $10,000 investment in INBX five years ago would be worth $25,954 today (with dividends reinvested), compared to $22,183 for RVMD. Over the past 12 months, INBX leads with a +459.5% total return vs RVMD's +150.4%. The 3-year compound annual growth rate (CAGR) favors RVMD at 56.2% vs INBX's 46.1% — a key indicator of consistent wealth creation.
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| YTD ReturnYear-to-date | -1.2% | +29.1% |
| 1-Year ReturnPast 12 months | +459.5% | +150.4% |
| 3-Year ReturnCumulative with dividends | +211.6% | +281.2% |
| 5-Year ReturnCumulative with dividends | +159.5% | +121.8% |
| 10-Year ReturnCumulative with dividends | +263.5% | +253.0% |
| CAGR (3Y)Annualised 3-year return | +46.1% | +56.2% |
Risk & Volatility
INBX is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than RVMD's 0.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RVMD currently trades 82.0% from its 52-week high vs INBX's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.74x | 0.99x |
| 52-Week HighHighest price in past year | $94.56 | $124.49 |
| 52-Week LowLowest price in past year | $10.81 | $29.17 |
| % of 52W HighCurrent price vs 52-week peak | +78.4% | +82.0% |
| RSI (14)Momentum oscillator 0–100 | 47.2 | 54.1 |
| Avg Volume (50D)Average daily shares traded | 165K | 3.2M |
Analyst Outlook
Wall Street rates INBX as "Buy" and RVMD as "Buy".
| Metric | INBXInhibrx Bioscienc… | RVMDRevolution Medici… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $122.25 |
| # AnalystsCovering analysts | 5 | 20 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Feb 26 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | 100 | 398.59 | +298.6% |
| Revolution Medicine… (RVMD) | 100 | 343.93 | +243.9% |
Inhibrx Biosciences… (INBX) returned +160% over 5 years vs Revolution Medicine… (RVMD)'s +122%. A $10,000 investment in INBX 5 years ago would be worth $25,954 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | $7M | $200000.00 | -97.0% |
| Revolution Medicine… (RVMD) | $0.00 | $0.00 | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -124.0% | 8437.9% | +6903.1% |
| Revolution Medicine… (RVMD) | -2.1% | -37.7% | -1718.4% |
Inhibrx Biosciences, Inc.'s net margin went from -124% (2016) to 8438% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Inhibrx Biosciences… (INBX) | -0.23 | 116.58 | +50787.0% |
| Revolution Medicine… (RVMD) | -0.85 | -5.95 | -600.0% |
Chart 5Free Cash Flow — 5 Years
Inhibrx Biosciences, Inc. generated $-197M FCF in 2024 (-143% vs 2021). Revolution Medicines, Inc. generated $-914M FCF in 2025 (-494% vs 2021).
INBX vs RVMD: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is INBX or RVMD a better buy right now?
Inhibrx Biosciences, Inc. (INBX) offers the better valuation at 0.6x trailing P/E, making it the more compelling value choice. Analysts rate Inhibrx Biosciences, Inc. (INBX) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — INBX or RVMD?
Over the past 5 years, Inhibrx Biosciences, Inc. (INBX) delivered a total return of +159.5%, compared to +121.8% for Revolution Medicines, Inc. (RVMD). A $10,000 investment in INBX five years ago would be worth approximately $26K today (assuming dividends reinvested). Over 10 years, the gap is even starker: INBX returned +263.5% versus RVMD's +253.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — INBX or RVMD?
By beta (market sensitivity over 5 years), Inhibrx Biosciences, Inc. (INBX) is the lower-risk stock at 0.74β versus Revolution Medicines, Inc.'s 0.99β — meaning RVMD is approximately 34% more volatile than INBX relative to the S&P 500. On balance sheet safety, Inhibrx Biosciences, Inc. (INBX) carries a lower debt/equity ratio of 6% versus 10% for Revolution Medicines, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — INBX or RVMD?
Inhibrx Biosciences, Inc. (INBX) is the more profitable company, earning 8438% net margin versus 0.0% for Revolution Medicines, Inc. — meaning it keeps 8438% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RVMD leads at 0.0% versus -1657.2% for INBX. At the gross margin level — before operating expenses — RVMD leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — INBX or RVMD?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is INBX or RVMD better for a retirement portfolio?
For long-horizon retirement investors, Inhibrx Biosciences, Inc. (INBX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.74), +263.5% 10Y return). Both have compounded well over 10 years (INBX: +263.5%, RVMD: +253.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between INBX and RVMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: INBX is a small-cap deep-value stock; RVMD is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.